ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.
A novel method to 3D print components for nuclear reactors, developed by the Department of Energy’s Oak Ridge National Laboratory, has been licensed by Ultra Safe Nuclear Corporation.
In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.
A team including researchers from the Department of Energy’s Oak Ridge National Laboratory has developed a digital tool to better monitor a condition known as Barrett’s esophagus, which affects more than 3 million people in the United States.
Research teams from the Department of Energy’s Oak Ridge National Laboratory and their technologies have received seven 2021 R&D 100 Awards, plus special recognition for a COVID-19-related project.
ORNL has licensed its wireless charging technology for electric vehicles to Brooklyn-based HEVO. The system provides the world’s highest power levels in the smallest package and could one day enable electric vehicles to be charged as they are driven at highway speeds.
A new tool that simulates the energy profile of every building in America will give homeowners, utilities and companies a quick way to determine energy use and cost-effective retrofits that can reduce energy and carbon emissions.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.